All In MedTech

FDA Clearance Tracker · P110019

Xience Skypoint Everolimus Eluting Coronary Stent System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Nov 1, 2011 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Nov 1, 2011

Approved

Time to decision

195 days

Received Apr 20, 2011. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P110019
Device name
Xience Skypoint Everolimus Eluting Coronary Stent System
Applicant location
Santa Clara, CA
Received
Apr 20, 2011
Decided
Nov 1, 2011
Decision
Approved
Supplements
134 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NIQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE XIENCE PRIME AND XIENCE PRIME LL EVEROLIMUS ELUTING CORONARY STENT SYSTEM. THIS DEVICE IS INDICATED FOR IMPROVING CORONARY LUMINAL DIAMETER IN PATIENTS WITH SYMPTOMATIC HEART DISEASE DUE TO DE NOVO NATIVE CORONARY ARTERY LESIONS (LENGTH <= 32 MM) WITH REFERENCE VESSEL DIAMETERS OF >= 2.25 MM TO <= 4.25 MM.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NIQ. The earliest in FDA's data is P020026, decided Apr 24, 2003.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott Vascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.